Cellectar Biosciences Inc (CLRB)

09:00 AM

Cellectar Biosciences Inc. Stock Analysis and ForecastPhenomenal capital gains - PrintWeekIndia

09:00 AM

02:52 AM

What institutions are buying Cellectar Biosciences Inc. stock nowFree Stock Market Return Analysis - jammulinksnews.com

02:52 AM

Jul 24, 2025

What drives Cellectar Biosciences Inc. stock priceMassive wealth growth - Autocar Professional

Jul 24, 2025

Jul 23, 2025

Is Cellectar Biosciences Inc. a good long term investmentSuperior stock selection - Autocar Professional

Jul 23, 2025

Jul 22, 2025

What analysts say about Cellectar Biosciences Inc. stockExceptional trading performance - Autocar Professional

Jul 22, 2025

Jul 17, 2025

Cellectar’s Cancer Therapy Hopes Face A Cash Crunch - Finimize

Jul 17, 2025

Jul 15, 2025

What makes Cellectar Biosciences Inc. stock price move sharplySafety First Trading Signals - Newser

Jul 15, 2025

Jul 15, 2025

All You Need to Know About Cellectar Biosciences (CLRB) Rating Upgrade to Buy - MSN

Jul 15, 2025

Jul 15, 2025

How Cellectar Biosciences Inc. stock performs during market volatilityRapid Gain Targets - Newser

Jul 15, 2025

Jul 15, 2025

Why Cellectar Biosciences Inc. stock attracts strong analyst attentionFree Stock Market Return Analysis - Newser

Jul 15, 2025

Jul 14, 2025

Waldenstrom Macroglobulinemia Market Sees Surging Demand Across the 7MM Amid BTK Inhibitor Advancements | DelveInsight - GlobeNewswire Inc.

Jul 14, 2025

Jul 06, 2025

Sequoia Financial Advisors LLC Purchases 188,760 Shares of Cellectar Biosciences, Inc. (NASDAQ:CLRB) - Defense World

Jul 06, 2025

Jul 03, 2025

Insider Buying: James Caruso Acquires 10,000 Shares of Cellectar Biosciences Inc (CLRB) - GuruFocus

Jul 03, 2025

Jul 02, 2025

Cellectar Biosciences Announces Closing of $6.9 Million - GlobeNewswire

Jul 02, 2025

Jul 02, 2025

Cellectar Biosciences Closes $6.9 Million Public Offering - MarketScreener

Jul 02, 2025

Jul 02, 2025

Cellectar Biosciences, Inc. Completes $6.9 Million Public Offering to Advance Cancer Treatment Development - Quiver Quantitative

Jul 02, 2025

Jul 02, 2025

Cellectar Secures $6.9M Funding: Healthcare Funds Back New Breast Cancer Drug Development - Stock Titan

Jul 02, 2025

Jul 01, 2025

Cellectar Biosciences Announces Pricing of $6 Million Underwritten Public Offering | CLRB Stock News - GuruFocus

Jul 01, 2025

Jul 01, 2025

Cellectar Biosciences prices $6 million public offering - Investing.com

Jul 01, 2025

Jul 01, 2025

Cellectar Biosciences, Inc. Announces Pricing of Underwritten Public Offering for Approximately $6 Million - Quiver Quantitative

Jul 01, 2025

Jul 01, 2025

Cellectar Biosciences prices $6 million public offering By Investing.com - Investing.com UK

Jul 01, 2025

Jun 30, 2025

Oncology Innovation Just Hit a Turning Point -- Here's What to Watch - The Globe and Mail

Jun 30, 2025

Jun 28, 2025

Cellectar Biosciences (NASDAQ:CLRB) Rating Increased to Sell at Wall Street Zen - Defense World

Jun 28, 2025

Jun 26, 2025

Cellectar Biosciences, Inc. and Nusano Enter into Multi-Isotope Supply Agreement - MarketScreener

Jun 26, 2025

Jun 26, 2025

Cellectar Biosciences provides update on clinical programs and preclinical data - Investing.com

Jun 26, 2025

Jun 26, 2025

Cellectar Biosciences enacts one-for-thirty reverse stock split on Nasdaq - Investing.com India

Jun 26, 2025

Jun 24, 2025

Cellectar Biosciences (CLRB) Submits Study Protocol to FDA for P - GuruFocus

Jun 24, 2025

Jun 24, 2025

Cellectar Biosciences Trading Halted: News Pending - AInvest

Jun 24, 2025

Jun 19, 2025

Cellectar Biosciences Announces One-for-Thirty Reverse Stock Split - The Manila Times

Jun 19, 2025

Jun 18, 2025

Cellectar Biosciences announces one-for-thirty reverse stock split - MarketScreener

Jun 18, 2025

Jun 18, 2025

Cellectar Biosciences (CLRB) Announces One-for-Thirty Reverse St - GuruFocus

Jun 18, 2025

Jun 18, 2025

Cellectar Biosciences announces 1:30 reverse stock split - Investing.com

Jun 18, 2025